o VB C-02 clinical trial with the therapeutic cancer vaccine VB10.16 and immune
checkpoint inhibitor atezolizumab (Tecentriq®) is on track to finalize
enrollment during fourth quarter 2021

o Per protocol interim safety analysis has been conducted as planned with no
safety concerns and a recommendation to continue the trial as planned

Oslo, Norway, April 30, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, announced that the Safety Review Committee meeting to evaluate
the per protocol Interim Safety Analysis for the VB C-02 trial concluded to
continue the recruitment as planned.

Investigational sites in 6 European countries are now screening and enrolling
patients in the VB C-02 clinical trial. The trial is expected to end the
enrolment period in fourth quarter 2021 and plans to report interim clinical
data around year-end.

The VB C-02 clinical trial is a multi-centre, open-label clinical trial testing
VB10.16, a targeted cancer vaccine, and immune checkpoint inhibitor atezolizumab
in patients with advanced HPV16 positive cervical cancer and will enroll up to
50 patients. The clinical trial has the ClinicalTrials.gov Identifier:
NCT04405349.

About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies. The Company
develops vaccines for the treatment cancer and infectious diseases. Vaccibody's
vaccine technology specifically targets antigens to Antigen Presenting Cells,
which are essential for inducing rapid, strong and long-lasting antigen-specific
immune responses and elicit efficacious clinical responses. Its lead product
candidates include VB10.NEO, a cancer neoantigen vaccine, which is exclusively
outlicensed to Genentech and is in phase I/IIa clinical trial for the treatment
of melanoma, lung- , head and neck, renal-, and bladder cancer